{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["flotetuzumab"]],"indication":"primary induction failure or early relapse AML","name":"VOYAGE","nct_id":"NCT02152956","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=voyage-nct02152956. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"VOYAGE","arms":[{"description":null,"label":"Cohort 0-a","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 0-b","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 0-c","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 0-d","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 1","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 2","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 2a","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 3","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 6","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 7","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 8","type":"EXPERIMENTAL"},{"description":null,"label":"MTD Expansion","type":"EXPERIMENTAL"},{"description":null,"label":"MTD expansion with Ruxolitinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-07-05","type":"ACTUAL"},"conditions":["AML"],"enrollment":{"count":244,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose","otherNames":["MGD006"],"type":"BIOLOGICAL"},{"name":"Ruxolitinib","otherNames":["Jakafi"],"type":"DRUG"},{"name":"Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2024-01-30","lead_sponsor":"MacroGenics","official_title":"A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2022-07-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Efficacy Based on CR or CRh Rate","timeFrame":"up to 14 months"}],"references":[{"citation":"Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis L, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Recher C, Stiff PJ, Pettit KM, Lowenberg B, Church SE, Anderson E, Vadakekolathu J, Santaguida M, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021 Feb 11;137(6):751-762. doi: 10.1182/blood.2020007732.","pmid":"32929488","type":"DERIVED"}],"start_date":{"date":"2014-06-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)","url":"https://clinicaltrials.gov/study/NCT02152956"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/voyage-nct02152956"}